CEO Prahlad R. Singh was paid $13,809,549 in fiscal year 2025, ↑ up 15.8% from fiscal year 2024, the 57th percentile of its disclosed peer group (SEC filing 0001193125-26-107266 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$13,809,549 ↑ Prahlad R. Singh total, FY2025 | 57th CEO pay percentile vs peers | 239:1 CEO-to-median pay ratio | 96.16% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
RVTY's next annual pay disclosure, estimated March 20, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Prahlad R. Singh | $1,129,231 | $0 | $7,694,985 | $2,559,152 | $2,385,450 | $0 | $40,731 | $13,809,549 |
| President and Chief Executive Officer | ||||||||
| Maxwell Krakowiak | 550,577 | 0 | 2,099,940 | 2,095,757 | 598,920 | 0 | 27,620 | 5,372,814 |
| Senior Vice President and Chief Financial Officer | ||||||||
| Miriame Victor | 503,269 | 0 | 1,530,069 | 1,526,916 | 509,082 | 0 | 26,738 | 4,096,074 |
| Senior Vice President and Chief Commercial Officer | ||||||||
| Joel S. Goldberg | 564,616 | 0 | 1,816,849 | 604,236 | 636,120 | 0 | 46,636 | 3,668,457 |
| Senior Vice President, Administration, General Counsel and Secretary | ||||||||
| Tajinder S. Vohra | 489,615 | 0 | 1,206,519 | 401,275 | 515,592 | 0 | 26,227 | 2,639,228 |
| Senior Vice President, Global Operations | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Prahlad R. Singh | $13,809,549 | $11,926,615 | $9,130,624 | ↑ +1,882,934 |
| Maxwell Krakowiak | 5,372,814 | 3,245,686 | 2,754,828 | ↑ +2,127,128 |
| Miriame Victor | 4,096,074 | 2,477,646 | 1,704,856 | ↑ +1,618,428 |
| Joel S. Goldberg | 3,668,457 | 3,381,566 | 2,644,742 | ↑ +286,891 |
| Tajinder S. Vohra | 2,639,228 | 2,309,353 | 1,760,975 | ↑ +329,875 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read REVVITY, INC.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper RVTY reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the REVVITY, INC. Peer Teardown Report
$13,809,549 Prahlad R. Singh total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 2, 2026 · Source: 0001193125-26-107266 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for RVTY
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order RVTY
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
Each company listed discloses RVTY in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named RVTY in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Get the REVVITY, INC. Executive Compensation Report
$1,500
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Prahlad R. Singh | CEO | $13,809,549 |
| Joel S. Goldberg | General Counsel | $3,668,457 |
| Maxwell Krakowiak | CFO | $5,372,814 |
| Miriame Victor | CCO | $4,096,074 |
| Tajinder S. Vohra | SVP | $2,639,228 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Alexis P. Michas | Chair of the Board | $449,981 |
| Frank R. Witney, PhD | Independent Director | $320,052 |
| Michael A. Klobuchar | Independent Director | $315,052 |
| Michel Vounatsos | Independent Director | $330,052 |
| Michelle McMurry-Heath, MD, PhD | Independent Director | $315,052 |
| Pascale Witz | Independent Director | $315,052 |
| Peter Barrett, PhD | Independent Director | $335,052 |
| Samuel R. Chapin | Independent Director | $340,052 |
| Sophie V. Vandebroek, PhD | Independent Director | $325,052 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Alexis P. Michas | Director | 2026-08-25 | D | 285 | $0 | $0 | Common, indirect | Form 4 ↗ |
| Tajinder S. Vohra | Please See Remarks | 2026-09-16 | D | 7,330 | 141 | 1,032,650 | Common | Form 4 ↗ |
| Maxwell Krakowiak | Please See Remarks | 2026-09-21 | D | 1,631 | 145 | 235,728 | Common | Form 4 ↗ |
| Anita Gonzales | VP and CAO | 2026-10-01 | D | 84 | 155 | 13,060 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Maxwell Krakowiak | RSU | 2025-02-04 | — | — | 5,709 | — | $699,980 |
| Maxwell Krakowiak | PSU | 2025-02-04 | 4,547 | 11,367 | — | 31,828 | 1,399,960 |
| Maxwell Krakowiak | OPTION | 2025-08-15 | — | — | 44,446 | — | 1,397,364 |
| Joel S. Goldberg | RSU | 2025-02-04 | — | — | 4,939 | — | 605,571 |
| Miriame Victor | PSU | 2025-02-04 | 3,313 | 8,282 | — | 23,190 | 1,020,011 |
| Prahlad R. Singh | PSU | 2025-02-04 | 16,661 | 41,653 | — | 116,628 | 5,129,983 |
| Miriame Victor | RSU | 2025-02-04 | — | — | 4,160 | — | 510,058 |
| Prahlad R. Singh | RSU | 2025-02-04 | — | — | 20,920 | — | 2,565,001 |
| Tajinder S. Vohra | OPTION | 2025-02-04 | — | — | 9,069 | — | 401,275 |
| Tajinder S. Vohra | RSU | 2025-02-04 | — | — | 3,280 | — | 402,161 |
| Tajinder S. Vohra | PSU | 2025-02-04 | 2,612 | 6,531 | — | 18,287 | 804,358 |
| Joel S. Goldberg | PSU | 2025-02-04 | 3,934 | 9,835 | — | 27,538 | 1,211,279 |
| Maxwell Krakowiak | OPTION | 2025-02-04 | — | — | 15,784 | — | 698,393 |
| Joel S. Goldberg | OPTION | 2025-02-04 | — | — | 13,656 | — | 604,236 |
| Prahlad R. Singh | OPTION | 2025-02-04 | — | — | 57,838 | — | 2,559,152 |
| Miriame Victor | OPTION | 2025-02-04 | — | — | 11,500 | — | 508,839 |
| Miriame Victor | OPTION | 2025-08-15 | — | — | 32,382 | — | 1,018,077 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Maxwell Krakowiak | $699,980 | $1,399,960 | $2,095,757 | 33.4% |
| Joel S. Goldberg | 605,571 | 1,211,279 | 604,236 | 50.0% |
| Miriame Victor | 510,058 | 1,020,011 | 1,526,916 | 33.4% |
| Prahlad R. Singh | 2,565,001 | 5,129,983 | 2,559,152 | 50.0% |
| Tajinder S. Vohra | 402,161 | 804,358 | 401,275 | 50.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Prahlad R. Singh | PSU | 41,653 | — | $4,029,928 |
| Miriame Victor | RSU | 4,263 | — | 412,445 |
| Prahlad R. Singh | Option | 57,838 | 123.35 | — |
| Miriame Victor | Option | 11,500 | 123.35 | — |
| Joel S. Goldberg | RSU | 7,136 | — | 690,408 |
| Maxwell Krakowiak | RSU | 9,342 | — | 18,686 |
| Miriame Victor | RSU | 4,088 | — | 2,045 |
| Maxwell Krakowiak | RSU | 5,709 | — | 552,346 |
| Joel S. Goldberg | Option | 18,352 | 104.64 | — |
| Miriame Victor | Option | 32,382 | 90.47 | — |
| Prahlad R. Singh | PSU | 39,702 | — | 3,841,169 |
| Prahlad R. Singh | RSU | 28,544 | — | 2,761,632 |
| Maxwell Krakowiak | RSU | 3,555 | — | 1,778 |
| Tajinder S. Vohra | RSU | 4,222 | — | 2,111 |
| Prahlad R. Singh | PSU | 39,702 | — | 3,841,169 |
| Prahlad R. Singh | RSU | 20,920 | — | 2,024,010 |
| Joel S. Goldberg | PSU | 9,925 | — | 960,244 |
| Miriame Victor | PSU | 7,002 | — | 677,444 |
| Maxwell Krakowiak | PSU | 6,024 | — | 582,822 |
| Miriame Victor | RSU | 4,160 | — | 402,480 |
| Maxwell Krakowiak | RSU | 3,012 | — | 291,411 |
| Tajinder S. Vohra | RSU | 2,201 | — | 212,947 |
| Joel S. Goldberg | RSU | 4,939 | — | 477,848 |
| Tajinder S. Vohra | PSU | 6,286 | — | 608,171 |
| Maxwell Krakowiak | RSU | 1,865 | — | 180,439 |
| Joel S. Goldberg | RSU | 6,843 | — | 3,422 |
| Tajinder S. Vohra | RSU | 4,402 | — | 425,894 |
| Prahlad R. Singh | RSU | 14,272 | — | 1,380,816 |
| Maxwell Krakowiak | PSU | 10,106 | — | 977,756 |
| Joel S. Goldberg | PSU | 9,835 | — | 951,536 |
| Miriame Victor | RSU | 2,132 | — | 206,271 |
| Joel S. Goldberg | RSU | 7,136 | — | 690,408 |
| Tajinder S. Vohra | PSU | 6,531 | — | 631,874 |
| Tajinder S. Vohra | PSU | 6,286 | — | 608,171 |
| Maxwell Krakowiak | RSU | 5,709 | — | 552,346 |
| Maxwell Krakowiak | Option | 2,889 | 133.2 | — |
| Tajinder S. Vohra | Option | 2,111 | 133.2 | — |
| Prahlad R. Singh | RSU | 28,544 | — | 2,761,632 |
| Tajinder S. Vohra | PSU | 6,531 | — | 631,874 |
| Joel S. Goldberg | PSU | 9,925 | — | 960,244 |
| Tajinder S. Vohra | RSU | 4,402 | — | 425,894 |
| Tajinder S. Vohra | RSU | 3,280 | — | 317,340 |
| Joel S. Goldberg | Option | 3,422 | 133.2 | — |
| Maxwell Krakowiak | Option | 18,686 | 104.64 | — |
| Miriame Victor | Option | 12,947 | 104.64 | — |
| Maxwell Krakowiak | Option | 44,446 | 90.47 | — |
| Tajinder S. Vohra | Option | 11,623 | 104.64 | — |
| Prahlad R. Singh | Option | 13,687 | 133.2 | — |
| Miriame Victor | PSU | 8,282 | — | 801,284 |
| Maxwell Krakowiak | PSU | 11,367 | — | 1,099,757 |
| Joel S. Goldberg | RSU | 3,568 | — | 345,204 |
| Miriame Victor | RSU | 4,160 | — | 402,480 |
| Tajinder S. Vohra | RSU | 3,280 | — | 317,340 |
| Prahlad R. Singh | PSU | 41,653 | — | 4,029,928 |
| Prahlad R. Singh | RSU | 20,920 | — | 2,024,010 |
| Maxwell Krakowiak | PSU | 10,106 | — | 977,756 |
| Joel S. Goldberg | PSU | 9,835 | — | 951,536 |
| Maxwell Krakowiak | PSU | 6,024 | — | 582,822 |
| Prahlad R. Singh | RSU | 36,703 | — | 73,408 |
| Tajinder S. Vohra | RSU | 5,811 | — | 11,623 |
| Miriame Victor | RSU | 6,473 | — | 12,947 |
| Maxwell Krakowiak | RSU | 5,777 | — | 2,889 |
| Joel S. Goldberg | RSU | 4,939 | — | 477,848 |
| Miriame Victor | PSU | 8,282 | — | 801,284 |
| Maxwell Krakowiak | PSU | 11,367 | — | 1,099,757 |
| Miriame Victor | RSU | 4,263 | — | 412,445 |
| Miriame Victor | RSU | 2,132 | — | 206,271 |
| Prahlad R. Singh | RSU | 14,272 | — | 1,380,816 |
| Miriame Victor | PSU | 7,002 | — | 677,444 |
| Joel S. Goldberg | RSU | 3,568 | — | 345,204 |
| Maxwell Krakowiak | RSU | 3,012 | — | 291,411 |
| Tajinder S. Vohra | RSU | 2,201 | — | 212,947 |
| Maxwell Krakowiak | RSU | 1,865 | — | 180,439 |
| Joel S. Goldberg | RSU | 9,176 | — | 18,352 |
| Prahlad R. Singh | RSU | 27,374 | — | 13,687 |
| Prahlad R. Singh | Option | 73,408 | 104.64 | — |
| Maxwell Krakowiak | Option | 15,784 | 123.35 | — |
| Joel S. Goldberg | Option | 13,656 | 123.35 | — |
| Miriame Victor | Option | 2,045 | 133.2 | — |
| Maxwell Krakowiak | Option | 1,778 | 133.2 | — |
We believe that pay should be performance-based, vary with the attainment of specific objectives, and be closely aligned with the interests of our shareholders.
| CEO STI target (% of salary) | 135% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | true |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-04-28 | 94,377,138 | 3,770,364 | 1,454,059 | 96.16% | Passed |
| 2025 | 2025-04-22 | 92,835,062 | 8,444,564 | 244,613 | 91.44% | Passed |
| 2024 | 2024-04-23 | 97,992,794 | 4,439,860 | 374,428 | 95.67% | Passed |
| 2023 | 2023-04-25 | 100,542,538 | 5,082,669 | 388,411 | 94.84% | Passed |
| 2022 | 2022-04-26 | 99,228,054 | 5,110,363 | 152,933 | 95.1% | Passed |
| 2021 | 2021-04-27 | 89,990,259 | 4,856,614 | 146,272 | 94.88% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-04-28 | 96.16%a |
| 2025 | 2025-04-22 | 91.44%b |
| 2024 | 2024-04-23 | 95.67%c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “Shares abstaining and broker non-votes, if any, will not be counted as votes for or against, and as a result will have no effect on voting on Proposals No. 1, 2, 3 or 5, other than for purposes of establishing a quorum.”.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 239 : 1 |
|---|---|
| CEO total compensation | $13,809,549 |
| Median employee compensation | $57,745 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Alexis P. MichasIndependent · Board Chair · Audit | $180,000 | $264,981 | $0 | $0 | $5,000 | $449,981 |
| Samuel R. ChapinIndependent · Audit (Chair) · Nominating and Corporate Governance | 115,000 | 225,052 | 0 | 0 | 0 | 340,052 |
| Peter Barrett, PhDIndependent · Compensation and Benefits (Chair) · Nominating and Corporate Governance | 110,000 | 225,052 | 0 | 0 | 0 | 335,052 |
| Michel VounatsosIndependent · Nominating and Corporate Governance (Chair) · Audit | 105,000 | 225,052 | 0 | 0 | 0 | 330,052 |
| Sophie V. Vandebroek, PhDIndependent · Audit | 90,000 | 225,052 | 0 | 0 | 10,000 | 325,052 |
| Frank R. Witney, PhDIndependent · Compensation and Benefits · Nominating and Corporate Governance | 90,000 | 225,052 | 0 | 0 | 5,000 | 320,052 |
| Michael A. KlobucharIndependent · Audit | 90,000 | 225,052 | 0 | 0 | 0 | 315,052 |
| Michelle McMurry-Heath, MD, PhDIndependent · Compensation and Benefits | 90,000 | 225,052 | 0 | 0 | 0 | 315,052 |
| Pascale WitzIndependent · Audit · Compensation and Benefits | 90,000 | 225,052 | 0 | 0 | 0 | 315,052 |
| Prahlad R. Singh, PhDEmployee director | 0 | 0 | 0 | 0 | 0 | 0 |
| Annual cash retainer | $90,000 |
|---|---|
| Annual equity retainer | $225,052 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 25,000 / 25,000 |
| Stock ownership guideline | $450,000 |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $960,000 |
| Equity awards (grant-date value) | $2,065,397 |
| All other compensation | $20,000 |
| Total cost of the board | $3,045,397 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies REVVITY, INC. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including REVVITY, INC..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific Inc. | 2025 | Marc Casper | $1,785,534 | $65,730,211 | $7,951,377 | $3,742,123 | $79,923,350 |
| 2 | IQVIA Holdings Inc. | 2025 | Ari Bousbib | 1,800,000 | 15,749,957 | 4,528,317 | 4,966,127 | 28,128,245 |
| 3 | Roper Technologies, Inc. | 2025 | L. Neil Hunn | 1,000,000 | 17,533,527 | 5,098,979 | 2,096,000 | 26,205,765 |
| 4 | Danaher Corporation | 2025 | Rainer Blair | 1,400,000 | 9,292,370 | 8,386,657 | 4,194,400 | 23,795,280 |
| 5 | Laboratory Corporation of America Holdings | 2025 | Adam Schechter | 1,435,000 | 11,400,463 | 2,754,582 | 2,062,095 | 18,339,913 |
| 6 | Becton, Dickinson and Company | 2025 | Thomas Polen | 1,395,463 | 9,991,854 | 3,311,861 | 1,852,010 | 17,129,140 |
| 7 | The Cooper Companies, Inc. | 2025 | Albert White III | 1,170,769 | 6,642,918 | 6,643,050 | 1,525,951 | 16,051,141 |
| 8 | Hologic, Inc. | 2024 | Stephen MacMillan | 1,212,628 | 9,141,468 | 2,937,477 | 1,990,413 | 15,819,261 |
| 9 | Exact Sciences Corporation | 2024 | Kevin Conroy | 1,083,368 | 13,496,138 | 0 | 712,329 | 15,539,378 |
| 10 | Quest Diagnostics Incorporated | 2025 | James Davis | 1,250,000 | 8,762,861 | 2,999,873 | 2,205,844 | 15,498,479 |
| 11 | Charles River Laboratories International, Inc. | 2025 | James Foster | 1,545,636 | 11,601,089 | 0 | 2,182,666 | 15,435,220 |
| 12 | Natera, Inc. | 2025 | Steven Chapman | 853,710 | 12,979,558 | 0 | 1,114,151 | 14,957,319 |
| 13 | Waters Corporation | 2025 | Udit Batra | 1,150,000 | 7,430,247 | 2,999,922 | 2,371,875 | 13,973,044 |
| 14 | REVVITY, INC. | 2025 | Prahlad R. Singh | 1,129,231 | 7,694,985 | 2,559,152 | 2,385,450 | 13,809,549 |
| 15 | Agilent Technologies, Inc. | 2025 | Padraig McDonnell | 1,141,345 | 8,169,850 | 2,017,759 | 1,436,809 | 12,827,236 |
| 16 | Haemonetics Corporation | 2026 | Christopher Simon | 1,100,008 | 7,561,987 | 1,504,968 | 1,834,250 | 12,044,701 |
| 17 | Medpace Holdings, Inc. | 2025 | August Troendle | 937,417 | 0 | 9,999,999 | 0 | 11,443,766 |
| 18 | QuidelOrtho Corporation | 2025 | Brian Blaser | 1,000,000 | 8,965,822 | 0 | 1,274,500 | 11,255,782 |
| 19 | Illumina, Inc. | 2025 | Jacob Thaysen | 1,000,000 | 8,763,122 | 0 | 1,155,000 | 11,018,895 |
| 20 | Neogen Corporation | 2026 | Mike Nassif | 630,769 | 3,250,000 | 3,250,000 | 1,000,000 | 8,693,916 |
| 21 | Bio-Techne Corporation | 2025 | Kim Kelderman | 936,000 | 3,929,942 | 1,932,848 | 1,318,917 | 8,151,181 |
| 22 | Bio-Rad Laboratories, Inc. | 2025 | Norman Schwartz | 1,089,877 | 4,856,574 | 1,458,975 | 562,088 | 7,995,841 |
| 23 | Mettler-Toledo International Inc. | 2025 | Patrick Kaltenbach | 1,145,999 | 3,267,808 | 1,635,033 | 462,984 | 6,741,212 |
| 24 | Teleflex Incorporated | 2025 | Liam Kelly | 1,144,400 | 2,005,604 | 2,886,518 | 227,280 | 6,732,419 |
| 25 | Catalent, Inc. | 2023 | Alessandro Maselli | 925,000 | 3,850,216 | 1,650,019 | 0 | 6,583,672 |
| 26 | 10X Genomics, Inc. | 2025 | Serge Saxonov | 674,250 | 5,020,269 | 0 | 634,725 | 6,329,244 |
| 27 | Repligen Corporation | 2025 | Olivier Loeillot | 860,000 | 3,374,853 | 1,095,626 | 774,000 | 6,114,771 |
| 28 | Avantor, Inc. | 2025 | Emmanuel Ligner | 379,297 | 2,499,990 | 2,499,998 | 330,038 | 5,895,624 |
| 29 | Myriad Genetics, Inc. | 2025 | Samraat Raha | 856,901 | 3,989,729 | 0 | 814,660 | 5,686,740 |
| 30 | Bruker Corporation | 2025 | Frank Laukien | 976,554 | 1,623,407 | 1,488,109 | 587,270 | 4,706,388 |
| 31 | Teledyne Technologies Incorporated | 2025 | George C. Bobb III | 816,827 | 601,546 | 1,730,522 | 1,080,908 | 4,255,049 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| REVVITY, INC. | 124% | PSU 50 · RSU 25 · Options 25 | No | Pearl Meyer |
| 10X Genomics, Inc. | 93% | PSU 60 · RSU 40 | Yes — 3-year Relative TSR | Alpine Rewards LLC |
| Agilent Technologies, Inc. | not disclosed | PSU 60 · Options 20 · RSU 20 | No | Semler Brossy |
| Avantor, Inc. | 56.9% | PSU 50 · Options 25 · RSU 25 | Yes — TSR Relative to Comparator Group | FW Cook |
| Becton, Dickinson and Company | 85% | PSU 50 · Options 25 · RSU 25 | No | Semler Brossy |
| Bio-Rad Laboratories, Inc. | not disclosed | not disclosed | not disclosed | Compensia, Inc. |
| Bio-Techne Corporation | 128.1% | PSU 50 · Options 25 · RSU 25 | No | Aon |
| Bruker Corporation | 43.0% | RSU 52 · Options 48 | not disclosed | Aon's Human Capital Solutions Practice |
| Catalent, Inc. | 0% | PSU 50 · Option 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| Charles River Laboratories International, Inc. | 139% | PSU 60 · RSU 40 | Yes — Three-year rTSR | Pay Governance |
| Danaher Corporation | not disclosed | Options 50 · RSU 50 | Yes — Relative TSR | FW Cook |
| Exact Sciences Corporation | 47% | PSU 60 · RSU 40 | No | Aon |
| Haemonetics Corporation | 133.4% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| Hologic, Inc. | 109% | PSU 50 · RSU 25 · Option 25 | No | Pearl Meyer & Partners, LLC |
| Illumina, Inc. | 1155% | not disclosed | Yes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology Index | Aon (Aon's Human Capital Practice, a division of Aon, plc) |
| IQVIA Holdings Inc. | not disclosed | PSU 75 · Options 25 | Yes | Meridian Compensation Partners, LLC |
| Laboratory Corporation of America Holdings | 95.8% | PSU 60 · RSU 20 · Options 20 | Yes — RELATIVE TSR MODIFIER | FW Cook |
| Medpace Holdings, Inc. | 52.5% | Options 100 | not disclosed | Total Compensation Solutions (TCS) |
| Mettler-Toledo International Inc. | not disclosed | not disclosed | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners |
| Myriad Genetics, Inc. | 89% | RSU 50 · PSU 50 | Yes | Mercer, LLC |
| Natera, Inc. | 131.1% | PSU 50 · RSU 50 | No | Aon |
| Neogen Corporation | not disclosed | PSU 50 · Option 50 | not disclosed | Farient Advisors, LLC |
| Quest Diagnostics Incorporated | 113.9% | PSU 50 · RSU 25 · Options 25 | Yes — Relative TSR | Semler Brossy |
| QuidelOrtho Corporation | 127% | PSU 60 · RSU 40 | Yes — Total Shareholder Return (TSR) | Compensia |
| Repligen Corporation | 100% | RSU 50 · PSU 25 · Options 25 | No | Meridian Compensation Partners, LLC |
| Roper Technologies, Inc. | 104.8% | PSU 75 · Options 25 | No | Compensia |
| Teledyne Technologies Incorporated | not disclosed | Options 33 · Cash LTI 33 · PSU 33 | No | Exequity |
| Teleflex Incorporated | 25.9% | Options 55 · RSU 25 · PSU 20 | Yes — Absolute TSR | FW Cook |
| The Cooper Companies, Inc. | 100.9% | Options 50 · PSU 50 | No | Compensia |
| Thermo Fisher Scientific Inc. | 99.8% | PSU 50 · Options 50 | Yes — Relative TSR | Pearl Meyer |
| Waters Corporation | 110% | PSU 50 · Options 35 · RSU 15 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Prahlad R. Singh | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “Summary Compensation Table”. As printed: 13,809,549. Filing ↗machine: r3 · c39 · span 751285–751295 |
| 2 | Section 01, Maxwell Krakowiak | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “Summary Compensation Table” · page 51. As printed: 5,372,814. Filing ↗machine: span 758643–758652 |
| 3 | Section 01, Miriame Victor | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “Summary Compensation Table” · page 51. As printed: 4,096,074. Filing ↗machine: span 778402–778411 |
| 4 | Section 01, Joel S. Goldberg | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “Summary Compensation Table”. As printed: 3,668,457. Filing ↗machine: r10 · c39 · span 766604–766613 |
| 5 | Section 01, Tajinder S. Vohra | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “Summary Compensation Table”. As printed: 2,639,228. Filing ↗machine: r18 · c39 · span 786256–786265 |
| 6 | Section 03, Maxwell Krakowiak RSU | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t183 · r24 · c24 · span 999742–999747 |
| 7 | Section 03, Maxwell Krakowiak PSU | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t174 · r8 · c57 · span 836647–836656 |
| 8 | Section 03, Maxwell Krakowiak OPTION | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t183 · r15 · c9 · span 961156–961162 |
| 9 | Section 03, Joel S. Goldberg RSU | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t183 · r34 · c24 · span 1034285–1034290 |
| 10 | Section 03, Miriame Victor PSU | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t174 · r17 · c57 · span 876405–876414 |
| 11 | Section 03, Prahlad R. Singh PSU | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t174 · r4 · c57 · span 819046–819055 |
| 12 | Section 03, Miriame Victor RSU | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t183 · r46 · c24 · span 1079356–1079361 |
| 13 | Section 03, Prahlad R. Singh RSU | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t183 · r12 · c24 · span 952136–952142 |
| 14 | Section 03, Tajinder S. Vohra OPTION | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t183 · r49 · c9 · span 1090561–1090566 |
| 15 | Section 03, Tajinder S. Vohra RSU | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t183 · r56 · c24 · span 1113151–1113156 |
| 16 | Section 03, Tajinder S. Vohra PSU | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t174 · r22 · c57 · span 898576–898583 |
| 17 | Section 03, Joel S. Goldberg PSU | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t174 · r13 · c57 · span 858817–858826 |
| 18 | Section 03, Maxwell Krakowiak OPTION | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t183 · r16 · c9 · span 965375–965381 |
| 19 | Section 03, Joel S. Goldberg OPTION | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t183 · r27 · c9 · span 1011692–1011698 |
| 20 | Section 03, Prahlad R. Singh OPTION | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t183 · r5 · c9 · span 929538–929544 |
| 21 | Section 03, Miriame Victor OPTION | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t183 · r39 · c9 · span 1049216–1049222 |
| 22 | Section 03, Miriame Victor OPTION | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t183 · r38 · c9 · span 1044997–1045003 |
| 23 | Section 07, pay ratio | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “CEO Pay Ratio”. As printed: 239 : 1. Filing ↗ |
| 24 | Section 08, Alexis P. Michas | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “Director Compensation”. As printed: 449,981. Filing ↗machine: t77 · r7 · c19 · span 342741–342871 |
| 25 | Section 08, Samuel R. Chapin | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “Director Compensation”. As printed: 340,052. Filing ↗machine: t77 · r4 · c19 · span 335690–335820 |
| 26 | Section 08, Peter Barrett, PhD | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “Director Compensation”. As printed: 335,052. Filing ↗machine: t77 · r3 · c19 · span 333486–333616 |
| 27 | Section 08, Michel Vounatsos | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “Director Compensation”. As printed: 330,052. Filing ↗machine: t77 · r9 · c19 · span 347555–347685 |
| 28 | Section 08, Sophie V. Vandebroek, PhD | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “Director Compensation”. As printed: 325,052. Filing ↗machine: t77 · r8 · c19 · span 345326–345456 |
| 29 | Section 08, Frank R. Witney, PhD | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “Director Compensation”. As printed: 320,052. Filing ↗machine: t77 · r10 · c19 · span 350134–350264 |
| 30 | Section 08, Michael A. Klobuchar | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “Director Compensation”. As printed: 315,052. Filing ↗machine: t77 · r5 · c19 · span 337922–338052 |
| 31 | Section 08, Michelle McMurry-Heath, MD, PhD | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “Director Compensation”. As printed: 315,052. Filing ↗machine: t77 · r6 · c19 · span 340140–340270 |
| 32 | Section 08, Pascale Witz | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “Director Compensation”. As printed: 315,052. Filing ↗machine: t77 · r11 · c19 · span 352358–352488 |
| 33 | Section 08, Prahlad R. Singh, PhD | DEF 14A | 2026-03-16 | 0001193125-26-107266 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 34 | Section 02, Alexis P. Michas 2026-08-25 | Form 4 | 2026-08-25 | 0001193125-26-365114 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Tajinder S. Vohra 2026-09-16 | Form 4 | 2026-09-18 | 0001193125-26-395510 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Maxwell Krakowiak 2026-09-21 | Form 4 | 2026-09-23 | 0001193125-26-399376 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Anita Gonzales 2026-10-01 | Form 4 | 2026-10-02 | 0001193125-26-412237 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 06, 2026 vote | Form 8-K | 2026-05-01 | 0001193125-26-201401 | Item 5.07 · say-on-pay result. As reported: 96.16% (votes for as printed: 94,377,138). Filing ↗ |
| 39 | Section 06, 2025 vote | Form 8-K | 2025-04-25 | 0001193125-25-096747 | Item 5.07 · say-on-pay result. As reported: 91.44% (votes for as printed: 92,835,062). Filing ↗ |
| 40 | Section 06, 2024 vote | Form 8-K | 2024-04-24 | 0001193125-24-110060 | Item 5.07 · say-on-pay result. As reported: 95.67% (votes for as printed: 97,992,794). Filing ↗ |
| 41 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 42 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 43 | Section 09b board cost (computed) | Computed | — | — | Cash 960,000 + equity 2,065,397 + all other 20,000 = 3,045,397, summed across the director compensation table rows.machine: formula: Σ = 3,045,397 |
| 44 | Thermo Fisher Scientific Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-144585 | CEO total compensation as printed in Thermo Fisher Scientific Inc.'s own proxy. As printed: 79,923,350. Filing ↗machine: span 973487–973497 |
| 45 | IQVIA Holdings Inc., Section 10b CEO total | DEF 14A | 2026-02-27 | 0001628280-26-012892 | CEO total compensation as printed in IQVIA Holdings Inc.'s own proxy. As printed: 28,128,245. Filing ↗machine: t232 · r4 · c10 · span 1613956–1613966 |
| 46 | Roper Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-145481 | CEO total compensation as printed in Roper Technologies, Inc.'s own proxy. As printed: 26,205,765. Filing ↗machine: r3 · c27 · span 804964–804974 |
| 47 | Danaher Corporation, Section 10b CEO total | DEF 14A | 2026-03-25 | 0000313616-26-000101 | CEO total compensation as printed in Danaher Corporation's own proxy. As printed: 23,795,280. Filing ↗machine: t122 · r2 · c21 · span 1070180–1070190 |
| 48 | Laboratory Corporation of America Holdings, Section 10b CEO total | DEF 14A | 2026-04-10 | 0001193125-26-150752 | CEO total compensation as printed in Laboratory Corporation of America Holdings's own proxy. As printed: 18,339,913. Filing ↗machine: t153 · r3 · c22 · span 3147696–3147706 |
| 49 | Becton, Dickinson and Company, Section 10b CEO total | DEF 14A | 2025-12-18 | 0001628280-25-057846 | CEO total compensation as printed in Becton, Dickinson and Company's own proxy. As printed: 17,129,140. Filing ↗machine: r2 · c27 · span 1173285–1173295 |
| 50 | The Cooper Companies, Inc., Section 10b CEO total | DEF 14A | 2026-02-24 | 0001628280-26-011110 | CEO total compensation as printed in The Cooper Companies, Inc.'s own proxy. As printed: 16,051,141. Filing ↗machine: t120 · r3 · c14 · span 744904–744914 |
| 51 | Hologic, Inc., Section 10b CEO total | DEF 14A | 2025-01-16 | 0001140361-25-001287 | CEO total compensation as printed in Hologic, Inc.'s own proxy. As printed: 15,819,261. Filing ↗machine: r2 · c25 · span 1549664–1549674 |
| 52 | Exact Sciences Corporation, Section 10b CEO total | DEF 14A | 2025-04-29 | 0001124140-25-000034 | CEO total compensation as printed in Exact Sciences Corporation's own proxy. As printed: 15,539,378. Filing ↗machine: span 1077855–1077865 |
| 53 | Quest Diagnostics Incorporated, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001140361-26-013356 | CEO total compensation as printed in Quest Diagnostics Incorporated's own proxy. As printed: 15,498,479. Filing ↗machine: r2 · c17 · span 699327–699337 |
| 54 | Charles River Laboratories International, Inc., Section 10b CEO total | DEF 14A | 2026-03-31 | 0001104659-26-037367 | CEO total compensation as printed in Charles River Laboratories International, Inc.'s own proxy. As printed: 15,435,220. Filing ↗machine: r1 · c53 · span 1119658–1119668 |
| 55 | Natera, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047770 | CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878 |
| 56 | Waters Corporation, Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149657 | CEO total compensation as printed in Waters Corporation's own proxy. As printed: 13,973,044. Filing ↗machine: r5 · c18 · span 568522–568533 |
| 57 | REVVITY, INC. (subject), Section 10b CEO total | DEF 14A | 2026-03-16 | 0001193125-26-107266 | CEO total compensation as printed in REVVITY, INC.'s own proxy. As printed: 13,809,549. Filing ↗machine: r3 · c39 · span 751285–751295 |
| 58 | Agilent Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-02-06 | 0001193125-26-040286 | CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. Filing ↗machine: r3 · c29 · span 1450982–1450992 |
| 59 | Haemonetics Corporation, Section 10b CEO total | DEF 14A | 2026-06-09 | 0000313143-26-000074 | CEO total compensation as printed in Haemonetics Corporation's own proxy. As printed: 12,044,701. Filing ↗machine: span 718173–718183 |
| 60 | Medpace Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-01 | 0001668397-26-000012 | CEO total compensation as printed in Medpace Holdings, Inc.'s own proxy. As printed: 11,443,766. Filing ↗machine: t43 · r3 · c9 · span 495770–495781 |
| 61 | QuidelOrtho Corporation, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001906324-26-000018 | CEO total compensation as printed in QuidelOrtho Corporation's own proxy. As printed: 11,255,782. Filing ↗machine: r4 · c24 · span 760612–760622 |
| 62 | Illumina, Inc., Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149669 | CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. Filing ↗machine: r4 · c14 · span 728526–728536 |
| 63 | Neogen Corporation, Section 10b CEO total | DEF 14A | 2026-08-21 | 0001193125-26-360742 | CEO total compensation as printed in Neogen Corporation's own proxy. As printed: 8,693,916. Filing ↗machine: span 1672214–1672223 |
| 64 | Bio-Techne Corporation, Section 10b CEO total | DEF 14A | 2025-09-19 | 0001308179-25-000599 | CEO total compensation as printed in Bio-Techne Corporation's own proxy. As printed: 8,151,181. Filing ↗machine: span 792074–792083 |
| 65 | Bio-Rad Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-03-25 | 0000012208-26-000020 | CEO total compensation as printed in Bio-Rad Laboratories, Inc.'s own proxy. As printed: 7,995,841. Filing ↗machine: r2 · c24 · span 654200–654209 |
| 66 | Mettler-Toledo International Inc., Section 10b CEO total | DEF 14A | 2026-03-18 | 0001174947-26-000389 | CEO total compensation as printed in Mettler-Toledo International Inc.'s own proxy. As printed: 6,741,212. Filing ↗machine: r2 · c7 · span 643529–643538 |
| 67 | Teleflex Incorporated, Section 10b CEO total | DEF 14A | 2026-04-13 | 0000096943-26-000039 | CEO total compensation as printed in Teleflex Incorporated's own proxy. As printed: 6,732,419. Filing ↗machine: span 558736–558745 |
| 68 | Catalent, Inc., Section 10b CEO total | DEF 14A | 2023-12-15 | 0001193125-23-295996 | CEO total compensation as printed in Catalent, Inc.'s own proxy. As printed: 6,583,672. Filing ↗machine: r3 · c31 · span 1055835–1055844 |
| 69 | 10X Genomics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001628280-26-027201 | CEO total compensation as printed in 10X Genomics, Inc.'s own proxy. As printed: 6,329,244. Filing ↗machine: r3 · c48 · span 583283–583292 |
| 70 | Repligen Corporation, Section 10b CEO total | DEF 14A | 2026-04-02 | 0001193125-26-140115 | CEO total compensation as printed in Repligen Corporation's own proxy. As printed: 6,114,771. Filing ↗machine: t16 · r4 · c2 · span 577065–577074 |
| 71 | Avantor, Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0001628280-26-021572 | CEO total compensation as printed in Avantor, Inc.'s own proxy. As printed: 5,895,624. Filing ↗machine: r3 · c9 · span 2130032–2130041 |
| 72 | Myriad Genetics, Inc., Section 10b CEO total | DEF 14A | 2026-04-14 | 0000899923-26-000031 | CEO total compensation as printed in Myriad Genetics, Inc.'s own proxy. As printed: 5,686,740. Filing ↗machine: r2 · c24 · span 792986–792996 |
| 73 | Bruker Corporation, Section 10b CEO total | DEF 14A | 2026-04-10 | 0001193125-26-151305 | CEO total compensation as printed in Bruker Corporation's own proxy. As printed: 4,706,388. Filing ↗machine: t77 · r2 · c18 · span 987303–987312 |
| 74 | Teledyne Technologies Incorporated, Section 10b CEO total | DEF 14A | 2026-03-12 | 0001193125-26-104187 | CEO total compensation as printed in Teledyne Technologies Incorporated's own proxy. As printed: 4,255,049. Filing ↗machine: r3 · c30 · span 1147322–1147331 |
| 75 | Section 10a, Waters Corporation reciprocity | DEF 14A | — | 0001193125-26-149657 | Waters Corporation names REVVITY, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 76 | Section 10a, QuidelOrtho Corporation reciprocity | DEF 14A | — | 0001906324-26-000018 | QuidelOrtho Corporation's most recent proxy was read; its disclosed peer group does not include REVVITY, INC.. Filing ↗ |
| 77 | Section 10a, Roper Technologies, Inc. reciprocity | DEF 14A | — | 0001193125-26-145481 | Roper Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include REVVITY, INC.. Filing ↗ |
| 78 | Section 10a, Teledyne Technologies Incorporated reciprocity | DEF 14A | — | 0001193125-26-104187 | Teledyne Technologies Incorporated names REVVITY, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 79 | Section 10a, Repligen Corporation reciprocity | DEF 14A | — | 0001193125-26-140115 | Repligen Corporation's most recent proxy was read; its disclosed peer group does not include REVVITY, INC.. Filing ↗ |
| 80 | Section 10a, 10X Genomics, Inc. reciprocity | DEF 14A | — | 0001628280-26-027201 | 10X Genomics, Inc.'s most recent proxy was read; its disclosed peer group does not include REVVITY, INC.. Filing ↗ |
| 81 | Section 10a, Mettler-Toledo International Inc. reciprocity | DEF 14A | — | 0001174947-26-000389 | Mettler-Toledo International Inc. names REVVITY, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 82 | Section 10a, Medpace Holdings, Inc. reciprocity | DEF 14A | — | 0001668397-26-000012 | Medpace Holdings, Inc. names REVVITY, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 83 | Section 10a, Haemonetics Corporation reciprocity | DEF 14A | — | 0000313143-26-000074 | Haemonetics Corporation names REVVITY, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 84 | Section 10a, Charles River Laboratories International, Inc. reciprocity | DEF 14A | — | 0001104659-26-037367 | Charles River Laboratories International, Inc. names REVVITY, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 85 | Section 10a, Agilent Technologies, Inc. reciprocity | DEF 14A | — | 0001193125-26-040286 | Agilent Technologies, Inc. names REVVITY, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 86 | Section 10a, Bruker Corporation reciprocity | DEF 14A | — | 0001193125-26-151305 | Bruker Corporation names REVVITY, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 87 | Section 10a, Avantor, Inc. reciprocity | DEF 14A | — | 0001628280-26-021572 | Avantor, Inc. names REVVITY, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 88 | Section 10a, IQVIA Holdings Inc. reciprocity | DEF 14A | — | 0001628280-26-012892 | IQVIA Holdings Inc.'s most recent proxy was read; its disclosed peer group does not include REVVITY, INC.. Filing ↗ |
| 89 | Section 10a, Neogen Corporation reciprocity | DEF 14A | — | 0001193125-26-360742 | Neogen Corporation's most recent proxy was read; its disclosed peer group does not include REVVITY, INC.. Filing ↗ |
| 90 | Section 10a, Quest Diagnostics Incorporated reciprocity | DEF 14A | — | 0001140361-26-013356 | Quest Diagnostics Incorporated names REVVITY, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 91 | Section 10a, Becton, Dickinson and Company reciprocity | DEF 14A | — | 0001628280-25-057846 | Becton, Dickinson and Company's most recent proxy was read; its disclosed peer group does not include REVVITY, INC.. Filing ↗ |
| 92 | Section 10a, Laboratory Corporation of America Holdings reciprocity | DEF 14A | — | 0001193125-26-150752 | Laboratory Corporation of America Holdings's most recent proxy was read; its disclosed peer group does not include REVVITY, INC.. Filing ↗ |
| 93 | Section 10a, Natera, Inc. reciprocity | DEF 14A | — | 0001104659-26-047770 | Natera, Inc. names REVVITY, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 94 | Section 10a, Teleflex Incorporated reciprocity | DEF 14A | — | 0000096943-26-000039 | Teleflex Incorporated's most recent proxy was read; its disclosed peer group does not include REVVITY, INC.. Filing ↗ |
| 95 | Section 10a, Bio-Techne Corporation reciprocity | DEF 14A | — | 0001308179-25-000599 | Bio-Techne Corporation names REVVITY, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 96 | Section 10a, The Cooper Companies, Inc. reciprocity | DEF 14A | — | 0001628280-26-011110 | The Cooper Companies, Inc. names REVVITY, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 97 | Section 10a, Danaher Corporation reciprocity | DEF 14A | — | 0000313616-26-000101 | Danaher Corporation's most recent proxy was read; its disclosed peer group does not include REVVITY, INC.. Filing ↗ |
| 98 | Section 10a, Catalent, Inc. reciprocity | DEF 14A | — | 0001193125-23-295996 | Catalent, Inc.'s most recent proxy was read; its disclosed peer group does not include REVVITY, INC.. Filing ↗ |
| 99 | Section 10a, Exact Sciences Corporation reciprocity | DEF 14A | — | 0001124140-25-000034 | Exact Sciences Corporation's most recent proxy was read; its disclosed peer group does not include REVVITY, INC.. Filing ↗ |
| 100 | Section 10a, Hologic, Inc. reciprocity | DEF 14A | — | 0001140361-25-001287 | Hologic, Inc. names REVVITY, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the REVVITY, INC. Executive Compensation Report
$1,500